Over half of all phase 3 clinical trials fail, with an estimated cost to a pharmaceutical company of between $800m to $1.4bn per drug failure. Only one in ten drugs make it through clinical trials to ...

Coverage from the panel discussion, "Can Clinical Pathways Have Burnout, Too?" at Patient-Centered Oncology Care 2023. While clinical pathways in oncology were initially integrated to guide ...

The integration of AI has the potential to enhance oncology clinical pathways, but there are important judgment calls that must be made before this technology can be fully implemented. The quest to ...

In the realm of oncology, the advent of clinical pathways has gained substantial traction in the past two decades as the increasing cost and complexity of cancer care demanded structured, ...

Preventing Future Harm: Identifying the Drivers of an Unsafe Discharge to Improve Safety on an Inpatient Oncology Service This study used claims and authorization data from a national insurer between ...

Children and young people (aged 0 to 24 years) with cancer should be offered the opportunity to take part in clinical trials if they are eligible. Involvement of children and young people with cancer ...